Putnam Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Putnam Investments’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-180,343	Closed	-$4.17M	–	1229
2023 Q1	$4.17M	Sell	180,343 -3,000	-2%	-$71.5K	0.01%	479
2022 Q4	$4.8M	Sell	183,343 -7,200	-4%	-$160K	0.01%	446
2022 Q3	$3.75M	Buy	+190,543	New	+$3.82M	0.01%	511
2022 Q2	–	Sell	-33,674	Closed	-$551K	–	1241
2022 Q1	$551K	Buy	33,674 +1,560	+5%	+$21.2K	﹤0.01%	972
2021 Q4	$523K	Buy	+32,114	New	+$457K	﹤0.01%	991

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Putnam Investments's KDNY Position: Q2 2023 in Review

Putnam Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 180,343 shares — an estimated $4.17M sold.

Putnam Investments first reported a position in KDNY in Q4 2021 and held it in 5 quarters. The position peaked at $4.8M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Putnam Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Putnam Investments sold 180,343 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.17M.
Putnam Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Putnam Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $4.8M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Putnam Investments's 13F filing for Q2 2023, filed 14 Aug 2023.